Fibroblast growth factor 21 (FGF21) has been identified as a potential therapeutic target in the treatment of T2D and NASH. The effectiveness of mRNAs was evaluated by 2 weeks of repeated subcutaneous administration in mice. This shows significant reductions in body weight and plasma insulin levels as well as hepatic steatosis. Here, INS is linked to fatty liver disease.